Dayle Hogg, DPhil

Dayle Hogg has broad commercial experience across business development, licensing (technology, new chemical entities), financing and valuation through working in biotechnology companies. Dayle was part of the team that secured the strategic investment from Takeda Research Investment Inc. and ‘Series A’ financing for Lectus Therapeutics Limited, in addition to a number of other commercial and licensing transactions. Prior to working with Lectus Therapeutics Limited, Dayle worked within Business Development at Sense Proteomic Limited. Dayle also has more than 10 years experience of ion channel physiology and pharmacology, is an inventor on a number of patent applications and an author of a number of publications in the ion channels field. Dayle has a DPhil in Pharmacology from the University of Oxford.